A daily look at the morning's key financial stories.
A number of companies including Mylan and Teva have disclosed subpoenas, Bloomberg reported.
CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.
Biotech stocks have been taking a beating, and traders see especially bad things ahead for one company.
Discussing why options traders are cautious about Teva Pharmaceuticals with CNBC contributor Mike Khouw.
Every pharma CEO needs to step up and say these outrageous drug-price hikes are not OK, says former Medtronic CEO Bill George. e.
Sanofi and its U.S. partner Regeneron could win U.S. approval for their keenly awaited new eczema drug dupilumab.
It's "certainly clear that there will be negative impact going forward," but one analyst said the stock has already seen the worst.
Jim Cramer spoke with Allergan CEO Brent Saunders on why the company will not engage in price gouging, and its latest acquisitions.
Jim Cramer shares his take on various caller stocks, including this pharma stock caught in the political pricing war.
Jim Cramer says the lack of common ground between Hillary Clinton and Donald Trump is causing uncertainty in the market.
After turning down Mylan's $26B offer, shares of Perrigo have lost almost half their value.
CNBC's Meg Tirrell reports the latest on the response from EpiPen maker Mylan to Sen. Chuck Grassley's inquiries over the controversial price hike for the drug.
The only way to stop drug companies from jacking up the costs of live-saving treatments is through price controls, a former Obama health advisor says.
Some are questioning whether Mylan's generic EpiPen may net the drugmaker more revenue than the original version.
There's a case for applying laws against profiteering to the drug industry, Dr. Joshua Sharfstein tells CNBC.
CNBC's Meg Tirrell reports on the fears in the biotech market following the Mylan EpiPen pricing saga, as well as the news that Mylan will launch a generic EpiPen auto-injector.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
CNBC's Meg Tirrell reports the latest on the drug price debate, Teva on a generic EpiPen and the FDA. David Maris, Wells Fargo analyst, and the "FMHR" traders weigh in.
Shares of Teva Pharmaceuticals fell as much as 6 percent after the U.S. Patent Office invalidated two of the company's patents.